The Universidad Rey Juan Carlos is set to launch a groundbreaking clinical trial investigating the potential of whole-body electromyostimulation (EMS) to aid functional recovery in post-COVID syndrome patients. As of January 2026, the study is listed as ‘Not yet recruiting’ on ClinicalTrials.gov, presenting a hopeful avenue for addressing long COVID symptoms.
In this article:
What changed?
Post-COVID syndrome, also known as long COVID, remains a complex challenge. Characterized by debilitating fatigue and other persistent symptoms, it affects millions globally. The Universidad Rey Juan Carlos’ newly announced study focuses on evaluating the safety and performance of a whole-body electromyostimulation suit in managing these symptoms. This marks a novel focus on utilizing a medical device for this condition, signaling progress in non-pharmacological treatment options.
What is the EMS suit and how does it work?
The device under trial, referred to as a whole-body electromyostimulation (EMS) suit, utilizes electrical impulses to stimulate multiple muscle groups. Intended for therapeutic purposes, EMS technology is already recognized in rehabilitation and athletic settings. This trial aims to extend its application to post-COVID-fatigue recovery.
The intended purpose of the device is to assist in restoring physical functionality by optimizing neuromuscular activation. According to information from related fields, EMS devices are typically designed to deliver low-level electrical stimulation safely. This process mimics natural muscle contractions, potentially reducing fatigue and improving endurance in patients with severe physical limitations.
What is the scope of this study?
This trial is sponsored by the Universidad Rey Juan Carlos and remains in the initial stages, with recruitment yet to begin. The planned intervention specifically targets individuals diagnosed with post-COVID syndrome and associated fatigue.
Although precise participant eligibility criteria are not detailed, the study’s outcomes will likely contribute valuable data on the device’s performance and safety. Trials like this one form the basis for regulatory assessments under international medical device regulations such as MDR Annex XIV, ensuring post-market monitoring and patient safety.
The findings could pave the way for the development of standardized device-based therapies for individuals suffering from long COVID symptoms if proven effective.
FAQ
- What is the expected timeline for the study?
As of January 2026, the study is listed as ‘Not yet recruiting,’ so recruitment and start dates are undefined. - Is this device available commercially?
Current indications suggest the device is experimental and intended for investigational use only at this stage. - Who can participate?
Participant eligibility specifics remain unclear but will likely involve individuals diagnosed with long COVID and symptoms of severe fatigue.
Conclusion
The Universidad Rey Juan Carlos is addressing a critical unmet need through this innovative clinical investigation into EMS technology for post-COVID syndrome. The results will provide insights into the potential safety and efficacy of this medical device for managing long COVID fatigue. Regulatory and clinical professionals should monitor this trial for evidence-based updates.
Disclaimer
This article is intended for informational purposes for clinical, quality, and regulatory professionals and does not constitute legal or medical advice. Readers should consult relevant specialists or documents for specific guidance.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07312357?term=medical+device